Microbiology & Infectious Diseases

The sudden discontinuation of quinidine, the only FDA-approved treatment for severe malaria in the U.S. in 2017, raises urgent ethical concerns about the responsibilities of pharmaceutical companies and the healthcare system’s capacity to protect patient care.

Syphilis rates remain alarmingly high among people living with HIV in Türkiye, particularly in younger men, according to a new large-scale cross-sectional study analyzing national laboratory data.

Climate change is accelerating the emergence and spread of dangerous fungal infections, expanding their range and resistance in ways that could reshape global public health.

The gut microbiome may hold untapped potential in managing pain related to orthopaedic conditions, according to a new integrative review that highlights its emerging role in modulating inflammation and neurological pathways.

A personalized approach to managing tuberculosis drug reaction with eosinophilia and systemic symptoms, or TB DRESS, is gaining momentum as clinicians face increasing challenges in treating tuberculosis in immunocompromised populations, particularly people living with HIV.

In a concerning development for infectious disease management, researchers have identified the emergence of ceftazidime-avibactam resistance in Klebsiella pneumoniae during the course of therapy, driven by novel mutations in KPC enzymes.

A new systematic review and meta-analysis reveals that the risk of rash in patients with infectious mononucleosis (IM) who are prescribed aminopenicillins is significantly lower than long believed, challenging decades-old assumptions in clinical practice.

In kidney transplant recipients (KTRs), delays in appropriate empiric antibiotic therapy for urosepsis significantly increase the risk of death, acute kidney injury (AKI), and graft failure, according to a post-hoc analysis of an observational study conducted at a tertiary transplant center.